Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy.
Elderly
Geriatric
Head-and-neck cancer
Immune checkpoint
Immunosenescence
Radiotherapy
Tumor-infiltrating lymphocytes
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
14 Nov 2022
14 Nov 2022
Historique:
received:
10
09
2022
accepted:
29
10
2022
entrez:
15
11
2022
pubmed:
16
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) are associated with locoregional control (LRC) in head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. As immunosenescence results in reduced immune activity, the role of TILs in elderly HNSCC patients may differ compared to younger patients, providing a rationale to study the prognostic role of TILs and immune checkpoints (ICs) in this population. Sixty-three HNSCC patients aged ≥ 65 years undergoing definitive (chemo)radiotherapy between 2010 and 2019 with sufficient material from pre-treatment biopsies were included in the analysis. Immunohistochemical stainings of CD3, CD4, CD8, PD-L1, TIM3, LAG3, TIGIT and CD96, and of osteopontin as an immunosenescence-associated protein were performed. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method, and Fine-Gray's models were used for locoregional failure (LRF) analyses. While there was no correlation between patient age and IC expression, osteopontin levels correlated with increasing age (r = 0.322, p < 0.05). Two-year OS, PFS, and LRC were 44%, 34%, and 71%, respectively. Increased LAG3 expression, both intraepithelial (SHR = 0.33, p < 0.05) and stromal (SHR = 0.38, p < 0.05), and elevated stromal TIM3 expression (SHR = 0.32, p < 0.05) corresponded with reduced LRFs. Absent tumoral PD-L1 expression (TPS = 0%) was associated with more LRFs (SHR = 0.28, p < 0.05). There was a trend towards improved LRF rates in elderly patients with increased intraepithelial CD3 + (SHR = 0.52, p = 0.07) and CD8 + (SHR = 0.52, p = 0.09) TIL levels. LAG3, TIM3 and TPS are promising biomarkers in elderly HNSCC patients receiving (chemo)radiotherapy. Considering the frequency of non-cancer related deaths in this population, the prognostic value of these biomarkers primarily relates to LRC.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Tumor-infiltrating lymphocytes (TILs) are associated with locoregional control (LRC) in head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. As immunosenescence results in reduced immune activity, the role of TILs in elderly HNSCC patients may differ compared to younger patients, providing a rationale to study the prognostic role of TILs and immune checkpoints (ICs) in this population.
MATERIAL AND METHODS
METHODS
Sixty-three HNSCC patients aged ≥ 65 years undergoing definitive (chemo)radiotherapy between 2010 and 2019 with sufficient material from pre-treatment biopsies were included in the analysis. Immunohistochemical stainings of CD3, CD4, CD8, PD-L1, TIM3, LAG3, TIGIT and CD96, and of osteopontin as an immunosenescence-associated protein were performed. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method, and Fine-Gray's models were used for locoregional failure (LRF) analyses.
RESULTS
RESULTS
While there was no correlation between patient age and IC expression, osteopontin levels correlated with increasing age (r = 0.322, p < 0.05). Two-year OS, PFS, and LRC were 44%, 34%, and 71%, respectively. Increased LAG3 expression, both intraepithelial (SHR = 0.33, p < 0.05) and stromal (SHR = 0.38, p < 0.05), and elevated stromal TIM3 expression (SHR = 0.32, p < 0.05) corresponded with reduced LRFs. Absent tumoral PD-L1 expression (TPS = 0%) was associated with more LRFs (SHR = 0.28, p < 0.05). There was a trend towards improved LRF rates in elderly patients with increased intraepithelial CD3 + (SHR = 0.52, p = 0.07) and CD8 + (SHR = 0.52, p = 0.09) TIL levels.
CONCLUSION
CONCLUSIONS
LAG3, TIM3 and TPS are promising biomarkers in elderly HNSCC patients receiving (chemo)radiotherapy. Considering the frequency of non-cancer related deaths in this population, the prognostic value of these biomarkers primarily relates to LRC.
Identifiants
pubmed: 36376922
doi: 10.1186/s13014-022-02153-9
pii: 10.1186/s13014-022-02153-9
pmc: PMC9661751
doi:
Substances chimiques
B7-H1 Antigen
0
Osteopontin
106441-73-0
Hepatitis A Virus Cellular Receptor 2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 413517907
Organisme : Deutsche Forschungsgemeinschaft
ID : 443978314
Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2021 Apr;62(4):471-478
pubmed: 32859699
Front Oncol. 2021 Nov 25;11:787864
pubmed: 34900743
Cancers (Basel). 2022 Jan 18;14(3):
pubmed: 35158740
Front Oncol. 2022 Jan 03;11:723716
pubmed: 35047384
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Cancer Immunol Res. 2019 Apr;7(4):559-571
pubmed: 30894377
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
Oral Oncol. 2018 Nov;86:81-90
pubmed: 30409325
J Hematol Oncol. 2020 Nov 10;13(1):151
pubmed: 33168037
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
Cancers (Basel). 2020 Jun 26;12(6):
pubmed: 32604773
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Int J Cancer. 2017 Aug 1;141(3):594-603
pubmed: 28480996
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209842
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
J Pers Med. 2021 Jul 10;11(7):
pubmed: 34357118
Clin Cancer Res. 2010 Nov 1;16(21):5091-3
pubmed: 20861165
Radiother Oncol. 2019 May;134:1-9
pubmed: 31005201
Biomedicines. 2021 Apr 28;9(5):
pubmed: 33925205
Front Immunol. 2022 Mar 25;13:783695
pubmed: 35401534
Clin Cancer Res. 2021 Jul 1;27(13):3620-3629
pubmed: 33883177
Int J Cancer. 2016 Jan 1;138(1):171-81
pubmed: 26178914
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529227
Oncoimmunology. 2018 Aug 23;7(11):e1502128
pubmed: 30377566
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Immun Ageing. 2020 Feb 12;17:3
pubmed: 32082401
Radiother Oncol. 2021 Jun;159:75-81
pubmed: 33753155
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Head Neck. 2019 Dec;41(12):4111-4120
pubmed: 31497915
Inflamm Regen. 2018 Dec 24;38:24
pubmed: 30603051
Lancet Oncol. 2005 Oct;6(10):757-64
pubmed: 16198981
Cell Physiol Biochem. 2018;45(2):720-732
pubmed: 29414812
Oncology. 2021;99(7):464-470
pubmed: 33789303
Clin Cancer Res. 2018 Mar 15;24(6):1364-1374
pubmed: 29298797
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Clin Invest. 2016 Dec 1;126(12):4626-4639
pubmed: 27820698
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Int J Cancer. 2013 Jan 15;132(2):E26-36
pubmed: 22890882
Mol Oncol. 2017 Feb;11(2):235-247
pubmed: 28102051
Radiother Oncol. 2021 Mar;156:281-293
pubmed: 33515668
Cell Death Dis. 2018 Mar 2;9(3):356
pubmed: 29500465
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Lancet Oncol. 2019 Oct;20(10):1349-1359
pubmed: 31416685
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Int J Oral Sci. 2020 May 28;12(1):16
pubmed: 32461587
Br J Cancer. 2014 Jan 21;110(2):501-9
pubmed: 24129245
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Oncoimmunology. 2021 Jul 25;10(1):1954761
pubmed: 34367732
Cell Oncol (Dordr). 2022 Feb;45(1):1-18
pubmed: 35015241
Clin Cancer Res. 2016 Jun 1;22(11):2639-49
pubmed: 26755529
Oncotarget. 2017 May 2;8(32):52889-52900
pubmed: 28881780
Mod Pathol. 2021 Jun;34(6):1125-1132
pubmed: 32759978
Radiother Oncol. 2021 Jan;154:276-282
pubmed: 33245947
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668519
Sci Rep. 2020 Feb 25;10(1):3360
pubmed: 32099066
Indian J Cancer. 2021 Jan 27;:
pubmed: 33753620
Front Immunol. 2022 Jan 17;12:785091
pubmed: 35111155
Theranostics. 2020 Jul 23;10(20):9395-9406
pubmed: 32802199
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75
pubmed: 17707270
Clin Pathol. 2020 Nov 12;13:2632010X20964846
pubmed: 33241207
Clin Transl Radiat Oncol. 2022 Feb 21;33:120-127
pubmed: 35243023
Oncoimmunology. 2016 Oct 7;5(11):e1239005
pubmed: 27999760
Clin Cancer Res. 2016 May 15;22(10):2565-74
pubmed: 26719427
Front Mol Biosci. 2021 Jul 23;8:619765
pubmed: 34368221
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15807-12
pubmed: 19805226
JAMA Otolaryngol Head Neck Surg. 2019 Nov 01;145(11):1012-1019
pubmed: 31486841
Gastric Cancer. 2020 Jan;23(1):95-104
pubmed: 31451991
PLoS One. 2015 Nov 12;10(11):e0142656
pubmed: 26562534
Oncotarget. 2016 Mar 15;7(11):12024-34
pubmed: 26918453
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671152
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Pol J Pathol. 2021;72(4):324-330
pubmed: 35308003
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560